Spectral Medical Inc. Announces Closing of Second Tranche of $14.0 Million Convertible Note Private Placement

TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”), is pleased to announce the closing of the second and final tranche of its previously announced $14.0 million private placement offering (the “Offering”) of convertible unsecured notes (the “2026 Notes”) due on November 1, 2031 (the “Maturity Date”). All dollar amounts in this news release are in Canadian dollars unless otherwise stated.